Biolegend, 100731, PerCP anti-mouse CD8a Antibody, 25μg

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PerCP under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.* PerCP has a maximum absorption of 482 nm and a maximum emission of 675 nm.
Excitation Laser: Blue Laser (488 nm)
Application Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).
Application References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Narusawa M, et al. 2014. Cancer Immunol Res. 2:568. PubMed Palacios-Arreola M, et al. 2017. Sci Rep. 10.1038/s41598-017-10135-1. PubMed Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed Gu J, et al. 2023. J Cell Biochem. 124:557. PubMed Wang YC, et al. 2023. J Exp Med. 220:. PubMed Yang Y, et al. 2023. Cancers (Basel). 15:. PubMed Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed Li T, et al. 2023. Nat Commun. 14:2498. PubMed Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed Wang Y, et al. 2023. iScience. 26:106630. PubMed Yang QC, et al. 2023. iScience. 26:106916. PubMed Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed Collin R, et al. 2020. J Immunol. 205:133. PubMed Wang L, et al. 2022. ACS Pharmacol Transl Sci. 5:110. PubMed Li M, et al. 2022. Cell Death Differ. 29:2034. PubMed Shen CY, et al. 2022. Pharmaceutics. 14: . PubMed Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed Singer M et al. 2016. Cell. 166(6):1500-1511 . PubMed Feola S, et al. 2022. Front Immunol. 13:826164. PubMed Fisher E, et al. 2021. Front Immunol. 11:602254. PubMed Khalsa JK, et al. 2020. Nat Commun. 3.175. PubMed Zhang L, et al. 2020. Front Oncol. 1.243055556. PubMed Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed Choudhari R, et al. 2016. Blood. 127: 1297 - 1306. PubMed Peng X, et al. 2014. J Immunol. 193:1268. PubMed Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed Yang X, et al. 2019. Oncotarget. 10:4180. PubMed Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed Li Y, et al. 2022. Clin Transl Immunology. 11:e1362. PubMed Collin R, et al. 2014. J Immunol. 193:3503. PubMed Ben-Shaanan T, et al. 2016. Nat Med. 10.1038/nm.4133. PubMed Dumas AA, et al. 2020. EMBO J. 39:e103790. PubMed Shields BD, et al. 2019. Cancer Res. 79:1113. PubMed Levi J, et al. 2020. J Nucl Med. . PubMed Wagle MV, et al. 2021. Nat Commun. 12:2782. PubMed Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed Leisegang M, et al. 2016. Clin Cancer Res. 22: 2734 - 2743. PubMed Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed Kondratieva T, et al. 2020. PLoS One. 15:e0239668. PubMed Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed Menotti M, et al. 2019. Nat Med. 25:130. PubMed Sood S, et al. 2016. J Immunol. 197: 429 - 440. PubMed Sun Z, Xiao Z 2013. Biochem Biophys Res Commun. 435:472. PubMed Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed Wang R, et al. 2022. Front Immunol. 13:947756. PubMed Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed Zhang X, et al. 2019. Nat Commun. 10:4158. PubMed Sandu I, et al. 2020. Cell Reports. 32(8):108078. PubMed Wuggenig P, et al. 2020. Commun Biol. 3:130. PubMed Guo S, et al. 2021. Sci Rep. 11:23745. PubMed Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed Hirata SI, et al. 2020. Allergy. 75:1939. PubMed Castiglioni P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. PubMed Yi H, et al. 2021. Front Immunol. 12:719189. PubMed Miyauchi E, et al. 2020. Nature. 585:102. PubMed Shibuya M, et al. 2021. iScience. 24:103131. PubMed Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed Li X, et al. 2016. MBio. 7: 02232-15. PubMed Roy S, et al. 2021. Nat Commun. 12:3182. PubMed Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed Chen C, et al. 2020. Cell Rep. 2136:30. PubMed Wang J, et al. 2019. Aging (Albany NY). 11:3463. PubMed Byrne K, et al. 2014. J Immunol. 192:1433. PubMed Hickey JW, et al. 2018. Biomaterials. 187:105. PubMed Hosaka K, et al. 2020. Nat Commun. 3.030555556. PubMed Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed Rinaldi S, et al. 2021. PLoS Pathog. 17:e1009533. PubMed Jacque E, et al. 2014. J Exp Med. 211:2085. PubMed Li X, et al. 2022. Cell Death Differ. . PubMed Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed Fan X, et al. 2014. PLoS One. 9:107638. PubMed Chen S, et al. 2018. Nat Commun. 9:5298. PubMed Cao Y, et al. 2022. Small. 18:e2203466. PubMed Bessell CA, et al. 2020. JCI Insight. 5:. PubMed Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID: AB_893427 (BioLegend Cat. No. 100731) AB_893423 (BioLegend Cat. No. 100732)
Structure: Ig superfamily, CD8α chain, 34 kD
Distribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function: Co-receptor for TCR
Ligand/Receptor: MHC class I molecule
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.
Gene ID: 12525
UniProt: View information about CD8alpha on UniProt.org
Clone: 53-6.7
Regulatory Status: RUO
Other Names: T8, Lyt2, Ly-2
Isotype: Rat IgG2a, κ
Q: How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?
A: PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.